Keros Therapeutics (KROS) Cash from Operations (2019 - 2025)
Keros Therapeutics posted quarterly Cash from Operations of 27292000.0 for Q4 2025, up 40.68% year-on-year from 19400073.17 in Q4 2024, and down 940.01% on a QoQ basis from 3249000.0 in Q3 2025.
Keros Therapeutics (KROS) has 7 years of Cash from Operations data on file, last reported at 27292000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Operations rose 40.68% year-over-year to 27292000.0; the trailing twelve-month figure through Dec 2025 stood at 107505000.0 (up 166.83% YoY), and the FY2025 full-year result was 107505000.0, up 166.83% from the prior year.
- Cash from Operations for Q4 2025 stood at 27292000.0, down from 3249000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 161171000.0 in Q1 2025 and bottomed at 46008000.0 in Q4 2024.
- The 5-year median for Cash from Operations is 25030500.0 (2022), against an average of 15504100.0.
- The widest annual swing landed in 2023, when Cash from Operations slumped 2299.09%; it then jumped 461.69% in 2025.
- A 5-year view of Cash from Operations shows it stood at 19565000.0 in 2021, then dropped by 9.6% to 21443000.0 in 2022, then retreated by 18.73% to 25459000.0 in 2023, then plunged by 80.71% to 46008000.0 in 2024, then soared by 40.68% to 27292000.0 in 2025.
- The last three Cash from Operations figures came in at 27292000.0 (Q4 2025), 3249000.0 (Q3 2025), and 29623000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.43 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.08 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.50 Mn |
| 10 | Keros Therapeutics | 403.85 Mn | 116.45 Mn | - | -27.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -27.29 Mn |
| Dec 31, 2025 | -27.29 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Sep 30, 2025 | 3.25 Mn |
| Jun 30, 2025 | -29.62 Mn |
| Jun 30, 2025 | -29.62 Mn |
| Mar 31, 2025 | 161.17 Mn |
| Mar 31, 2025 | 161.17 Mn |
| Dec 31, 2024 | -46.01 Mn |
| Dec 31, 2024 | -46.01 Mn |
| Sep 30, 2024 | -30.50 Mn |
| Sep 30, 2024 | -30.50 Mn |
| Jun 30, 2024 | -39.80 Mn |
| Jun 30, 2024 | -39.80 Mn |
| Mar 31, 2024 | -44.56 Mn |
| Mar 31, 2024 | -44.56 Mn |
| Dec 31, 2023 | -25.46 Mn |
| Dec 31, 2023 | -25.46 Mn |
| Sep 30, 2023 | -33.98 Mn |
| Sep 30, 2023 | -33.98 Mn |
| Jun 30, 2023 | -30.83 Mn |
| Jun 30, 2023 | -30.83 Mn |
| Mar 31, 2023 | -34.24 Mn |
| Mar 31, 2023 | -34.24 Mn |
| Dec 31, 2022 | -21.44 Mn |
| Dec 31, 2022 | -21.44 Mn |
| Sep 30, 2022 | -24.60 Mn |
| Sep 30, 2022 | -24.60 Mn |
| Jun 30, 2022 | -22.59 Mn |
| Jun 30, 2022 | -22.59 Mn |
| Mar 31, 2022 | -1.43 Mn |
| Mar 31, 2022 | -1.43 Mn |
| Dec 31, 2021 | -19.57 Mn |
| Dec 31, 2021 | -19.57 Mn |
| Sep 30, 2021 | -14.44 Mn |
| Sep 30, 2021 | -14.44 Mn |
| Jun 30, 2021 | -17.64 Mn |
| Jun 30, 2021 | -17.64 Mn |
| Mar 31, 2021 | -10.51 Mn |
| Mar 31, 2021 | -10.51 Mn |
| Dec 31, 2020 | -7.99 Mn |
| Dec 31, 2020 | -7.99 Mn |
| Sep 30, 2020 | -10.86 Mn |
| Sep 30, 2020 | -10.86 Mn |
| Jun 30, 2020 | -9.93 Mn |
| Jun 30, 2020 | -9.93 Mn |
| Mar 31, 2020 | -8.12 Mn |
| Mar 31, 2020 | -8.12 Mn |
| Dec 31, 2019 | -5.50 Mn |
| Dec 31, 2019 | -5.50 Mn |
| Sep 30, 2019 | -2.96 Mn |
| Sep 30, 2019 | -2.96 Mn |
| Jun 30, 2019 | -5.03 Mn |
| Jun 30, 2019 | -5.03 Mn |
| Mar 31, 2019 | -2.51 Mn |
| Mar 31, 2019 | -2.51 Mn |